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Regulatory T cells (Treg) play a key role in the impaired immune response that is typical for a chronic Hepatitis B virus (HBV) infection. To
gain more insight in the mechanism that is responsible for this impaired immune response, the effect of viral load reduction resulting from
treatment with the nucleotide analogue adefovir dipivoxil on the percentages of Treg and HBV-specific T-cell responses was analyzed. Peripheral
blood mononuclear cells (PBMC) of 12 patients were collected at baseline and during treatment. In parallel to the decline in viral load, we found a
decline in circulating Treg, combined with an increase in HBV core antigen-specific IFN-γ production and proliferation. The production of IL10
did not decrease during therapy. In conclusion, adefovir induced viral load reduction results in a decline of circulating Treg together with a partial
recovery of the immune response.
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Hepatitis B virus (HBV) is a common non-cytopathic DNA
virus. Infection with HBV in adults usually results in a self-
limiting, acute hepatitis, which confers protective immunity and
causes no further disease. In 10% of infected adults, HBV leads
to a chronic infection. Chronic HBV infection is an important
risk factor for the development of liver cirrhosis and
hepatocellular carcinoma. Worldwide 400 million people suffer
from a chronic HBV infection and approximately 1 million
people die annually from HBV-related disease (Lee, 1997; Lok
et al., 2001).
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doi:10.1016/j.virol.2006.11.018(IFN-γ) production is important for control of the infection
(Bertoletti and Naoumov, 2003; Rehermann et al., 1995).
Patients with a chronic HBV infection lack such a vigorous
multispecific T-cell response, but instead exhibit a weak or
undetectable virus-specific T-cell response (Bertoletti and
Naoumov, 2003). Patients with a chronic HBV infection have
increased percentages of CD4+CD25+ regulatory T cells (Treg)
in their peripheral blood. Treg are capable of inhibiting the
HBV-specific immune response in a dose dependent manner
and depletion of Treg results in an increased proliferation and
IFN-γ production against HBV core antigen (HBcAg) (Stoop et
al., 2005). In addition, Xu et al. recently showed that patients
with a high viral load have more peripheral Treg as compared to
patients with a low viral load (Xu et al., 2006). It has been
suggested that Treg can be induced through a repetitive
stimulation of T cells by the presence of high concentrations
of antigen for longer periods of time (Taams et al., 2002). The
high viral load present in peripheral blood of HBV patients
could possibly provide such a stimulus.
One of the therapeutic options for patients with a chronic
HBV infection is antiviral treatment with nucleos(t)ide analogs
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adefovir, an acyclic phosphonated adenine nucleotide analogue.
Intracellularly, adefovir dipivoxil undergoes two phosphoryla-
tion steps to compete with deoxyadenosine triphosphate to
inhibit viral DNA polymerase and HBV reverse transcriptase,
resulting in chain termination of DNA synthesis (Asmuth et al.,
2004).
The aim of this study was to determine how the decrease
in viral load and antigenic pressure affects the percentage of
Treg and the antiviral immune response, as tested by T-cell
proliferation, IFN-γ and IL10 production.
Results
HBV DNA decreased and alanine aminotransferase levels
normalized during adefovir treatment
Serum HBV DNA level and alanine aminotransferase level
(ALT) were determined at baseline, as well as after 3 and 6
months of treatment (Fig. 1). The median reduction in serum
HBV DNA from baseline to month six was 5.2 log10. Six
months of treatment led to undetectable HBV DNA in nine
(75%) patients and to normalization of the ALT levels inFig. 1. (A) The serum HBV DNA levels of the 12 patients at baseline after 3
months and after 6 months of adefovir therapy. The bar represents the median
serum HBV DNA level. (B) The serum ALT levels of the 12 patients at baseline
after 3 months and after 6 months of adefovir therapy. The bar represents the
median serum ALT level. HBV DNA and ALT levels were significantly lower at
3 and 6 months compared to baseline (p<0.05).eight (66%) patients; eight (66%) patients reached both
endpoints. Three patients had seroconversion from HBeAg to
anti-HBeAg during treatment. No patient exhibited loss of
serum HBsAg.
The proportion peripheral blood Treg decreased during
adefovir induced viral load reduction
To assess the effect of treatment with adefovir on the
immune response, we first determined the proportion of Treg
from cells that stained positive for CD4. Treg were defined as
the percentage of cells positive for CD4, CD25, CD45RO and
CTLA-4 divided by the percentage CD4 positive cells (Fig.
2A). After 3 and 6 months of therapy, we found a significant
decrease in the percentage of Treg (baseline 4.0±0.4 vs. 3
months 3.2±0.3 vs. 6 months 3.3±0.4, p=0.019 and p=0.037
respectively; Fig. 2B). A weak correlation was observed
between the percentage decrease in HBVDNA and the
percentage decrease in the proportion of Treg (r=0.384 and
p<0.05; data not shown).
Since FoxP3 is considered to be the most specific marker
for Treg, we also performed a flow cytometry staining with
antibodies against CD4, CD25 and FoxP3 in four of our
patients (Fig. 3A). For this the percentage of cells that stained
positive for CD4, CD25 and FoxP3 was divided by the
proportion of CD4 positive cells. All four patients had a
decrease in the proportion of Treg (10% decrease±3.5%) du-
ring the first 3 months of treatment. After 6 months of treat-
ment, the proportion of Treg increased somewhat, but re-
mained lower than at baseline. These results concurred with
the CD4, CD25, CD45RO and CTLA-4 Treg staining for all
four patients (Fig. 3B). To determine whether the CD4+
CD25+CTLA-4+ cells are FoxP3+ Treg, flow cytometry was
performed with those four markers on PBMC from healthy
controls. FoxP3 was expressed by 97% of the CD4+CD25+
CTLA-4+ cells. One representative healthy control is depic-
ted in Fig. 3C.
Proliferation and IFN-γ production increased during adefovir
induced viral load reduction
To determine the (HBV) specific proliferation and IFN-γ
production, PBMC collected at baseline and during therapy
were stimulated with HBcAg or tetanus toxin. As compared
to baseline the HBcAg specific proliferation had increased
both after 3 and 6 months of adefovir treatment (baseline
2893 CPM±689 vs. 3 months 5372 CPM±1382 vs. 6 months
4287 CPM±906; Fig. 4A). A similar increase was found for
the proliferation to tetanus toxin (Fig. 4B). The percentage
decrease in HBV DNA and the percentage increase in
proliferation to HBcAg were weakly correlated (r=0.371 and
p<0.05; data not shown).
PBMC from healthy controls did not proliferate upon
stimulation with HBcAg (data not shown).
In parallel, the number of IFN-γ producing cells as deter-
mined by Elispot significantly increased during treatment
both to HBcAg (5.7 spots/100,000 cells±1.8 at baseline vs.
Fig. 3. (A) The Treg staining was performed with antibodies against CD4,
CD25 and FoxP3. The cells depicted in the gate of the left dot plot are CD4+
and are depicted in the right dot plot. The cells in the upper right quadrant of
the right dot plot are CD4+CD25+FoxP3+ and are considered to be Treg. The
gates were set using isotype matched control antibodies. (B) The percentage of
Treg defined as the percentage of CD4+CD25+FoxP3+ cells divided by the
percentage of CD4+ cells (line and right y-axis) or the percentage of CD4+
CD25+CD45RO+CTLA-4+ cells divided by the percentage of CD4+ cells
(bars and left y-axis) (n=4). The change in percentage of Treg follows the
same trend for both staining methods. Data are expressed as mean±SEM. (C)
Flow cytometry staining experiment from a representative healthy control. The
staining was performed using antibodies against CD4, CD25, CTLA-4 and
FoxP3. The cells depicted in the gate of the left dot plot are CD4+CD25+ and
are depicted in the right dot plot. The cells in the upper right quadrant of the
right dot plot are CD4+CD25+CTLA-4+FoxP3+. The gates were set using
isotype matched control antibodies.
Fig. 2. (A) Flow cytometry staining experiment from a representative patient.
The Treg staining was performed using antibodies against CD4, CD25,
CD45RO and CTLA-4. The cells depicted in the upper right quadrant of the left
dot plot are CD4+CD25+ and are depicted in the right dot plot. The cells in the
upper right quadrant of the right dot plot are CD4+CD25+CD45RO+CTLA-4+
and are considered to be Treg. The gates were set using isotype matched control
antibodies. (B) The percentage of Treg defined as the percentage of cells that
stained positive for CD4, CD25, CD45RO and CTLA-4 divided by the
percentage of cells that stained positive for CD4. The dotted lines represent the
individual patients and the solid line depicts the mean percentage Treg. *p<0.05
compared to baseline.
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100,000 cells±5.0 at 6 months, p=0.014 and p=0.014 res-
pectively; Fig. 4C) as well as to tetanus toxin (Fig. 4D).
Adefovir induced viral load reduction did not lead to a reduced
IL10 production
Since clearance of HBV requires a cytokine response
with a T helper 1 type profile, we determined the effect of
adefovir therapy on the anti-inflammatory cytokine IL10.
For this purpose, PBMC collected at baseline and during
therapy were stimulated with HBcAg or with PHA as a
positive control. The number of IL10 producing cells was
determined by Elispot. Treatment resulted in a non-significant
increase (baseline vs. 6 months; p=0.155) in the number of
IL10 producing cells upon stimulation with HBcAg (base-
line 24.9 spots/100,000 cells±6.6 vs. 3 months 28.7 spots
100,000 cells±8.11 vs. 6 months 37.6 spots/100,000 cells±
8.0; Fig. 5).Adefovir had no direct effect on PBMC
The increased proliferation of PBMC upon stimulation with
HBcAg during adefovir treatment could be caused by a direct
effect of adefovir on PBMC or by decrease in viral load. PMEA
Fig. 4. PBMC obtained at baseline, after 3 months and after 6 months of treatment were stimulated for 6 days with HBcAg (A) or tetanus toxin (B). The proliferation
was determined by the incorporation of [3H]-thymidine. PBMC were also stimulated for 48 h with HBcAg (C) or tetanus toxin (D). IFN-γ production was determined
by Elispot. The dotted lines represent the individual patients and the solid line depicts the mean, *p<0.05 compared to baseline.
144 J.N. Stoop et al. / Virology 361 (2007) 141–148is the active metabolite of adefovir. To examine whether PMEA
has a direct stimulatory activity, PBMC from untreated HBV
patients were stimulated with HBcAg in culture medium
supplemented with different concentrations of PMEA. This
agent had no direct stimulatory effect resulting in proliferation
(Fig. 6A) or IL10 production (Fig. 6B; n=6). When stimulated
with HBcAg, different concentrations of PMEA had also no
effect on the proliferation of PBMC (Fig. 6A) or the number of
IL10 producing cells (Fig. 6B).
Discussion
Patients with chronic HBV infection lack the vigorous
multispecific CD4+ and CD8+ T-cell response with a type 1
cytokine profile necessary to clear the infection (Bertoletti et al.,
1997; Bertoletti and Naoumov, 2003). The precise mechanism
responsible for this impaired T-cell response is not known. Treg
represent a unique lineage of T cells with a critical role in
maintaining immune homeostasis. Treg are very potent
suppressors of the immune response. It has recently beenshown that a slight decrease in percentage of Treg (1.3%) can
result in the development of autoimmune disease (Lan et al.,
2006). Previously, we have shown that Treg contribute to the
impaired immune response in patients with a chronic HBV
infection by inhibiting the proliferation and IFN-γ production to
HBcAg in a dose dependent manner (Stoop et al., 2005). Treg
are also capable of inhibiting the proliferation and IFN-γ
production of HBV-specific CD8+ T cells (Franzese et al.,
2005).
In the current study we observed a decrease in the per-
centage of Treg after the first 3 months of adefovir treatment,
the time-period in which the most prominent decrease in viral
load occurs. Simultaneously we observed an increase in the
proliferation and the number of IFN-γ producing cells upon
stimulation with HBcAg. This increased response to HBcAg is
most likely an increase in CD4+ T-cell functioning since HBcAg
has been described to induce predominantly a CD4+ T-cell
response (Lau et al., 2002). After 6 months of adefovir treatment
there was no further decline in Treg and no further increase in the
number of IFN-γ producing cells and proliferation to HBcAg.
Fig. 5. PBMC from baseline, after 3 months and after 6 months of treatment
were stimulated for 48 h with (A) HBcAg or (B) PHA. The IL10 production was
determined by Elispot. The dotted lines represent the individual patients and the
solid line depicts the mean.
Fig. 6. PBMC were stimulated for 6 days with HBcAg antigen (n=6) in the
presence of different concentrations of PMEA. (A) The proliferation was
determined by the incorporation of [3H]-thymidine. (B) PBMC were stimulated
for 48 h with HBcAg (n=6) in the presence of different concentrations of
PMEA. The HBcAg specific IL10 production was determined by Elispot (n=6).
Data are expressed as mean±SEM.
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during this period. This indicates that the percentage of Treg
in the peripheral blood inversely correlates to the viral load.
Furthermore, we showed that PMEA, the working metabolite
of adefovir, has no direct effect on the proliferation and
cytokine production to HBcAg. In addition, in vitro treat-
ment with PMEA also had no effect on the proportion of
Treg in the PBMC fraction (data not shown). The increased
response we observed is therefore not caused by a direct
effect of adefovir on the HBcAg specific proliferation. Since
we have compared the proportion of Treg in peripheral
blood and not the absolute number, the relative decrease in
Treg could be caused by an increase in the number of res-
ponder T cells. However, if this is the case, adefovir induced
viral load reduction still leads to a more favorable balance
between effector and suppressor (Treg) T cells in the peri-
pheral blood.
It has been suggested that Treg can be induced through a
repetitive stimulation of T cells by high concentrations of
antigen for longer periods of time (Taams et al., 2002). Adefovir
inhibits viral replication and antigen production, which could
potentially result in a decrease of Treg induction, leading to
restoration of the immune response. In a previous study it was
shown that lamivudine-induced reduction of viral load resulted
in an increased CD4+ and CD8+ T-cell response (Boni et al.,
1998, 2003). Most likely, this increased immune reactivity onlamivudine may also have been the result of a decrease in the
percentage of Treg.
In the current study and previously, we determined the
percentage of Treg with antibodies against CD4, CD25,
CTLA-4 and CD45RO (Stoop et al., 2005). Recently, an
antibody against FoxP3 has become available. The transcrip-
tion factor FoxP3 is the most specific marker for Treg
(Fontenot et al., 2003; Hori et al., 2003). Therefore, we also
used a Treg staining with antibodies against CD4, CD25 and
FoxP3. Both staining methods showed the same trend,
however with the CD4+CD25+CD45RO+CTLA-4+ antibody
staining, we detected lower percentages of Treg compared to
the FoxP3 antibody staining. Treg are CD4+ cells known to
have high CD25 expression (Baecher-Allan et al., 2001). In the
current study, all CD4+CD25high cells expressed FoxP3 (Fig.
3A). Additional flow cytometry experiments revealed that 97%
of the CD4+CD25+CTLA-4+ cells expressed FoxP3, but not
all FoxP3 positive cells expressed CTLA-4 (data not shown).
Since CTLA-4 might have a functional role in the Treg-
induced immune suppression, CTLA-4 positive Treg could
well represent an activated sub-population of the FoxP3+ Treg
Table 1
Patient characteristics at baseline (n=12)
Sex 10 male (83%)
Age 48 (28–67) a years
HBV DNA (copies/ml) 1.69×108 (2.00×104–2.14×109) a
Race Asian: 5 (42%)
Caucasian: 7 (58%)
ALT (units/l) 119 (43–467) a
HBeAg positive 6 (50%)
Cirrhosis 2 (17%)
Previous treatment Treatment naive: 7 (58%)
PEG interferon+ lamivudine: 3 (25%)
Entecavir: 2 (17%)
a Median (range).
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Shevach, 2000).
The response to the control antigen (tetanus toxin) was also
increased. This could be explained by a decrease in activated
HBV-specific Treg. Treg have to be activated through their T-
cell receptor, but once activated the suppression by Treg is non-
specific (Jonuleit et al., 2001; Thornton and Shevach, 2000).
Therefore, the decrease in viral load will result in less HBV-
specific activated Treg capable of inhibiting the response of also
non-HBV-specific T cells.
The number of IL10 producing cells was not reduced
during treatment. The lack in decrease of cells producing this
immunoregulatory cytokine could be one of the reasons that
antiviral therapy does not lead to a sustained antiviral res-
ponse, but also suggests that Treg are not solely responsible
for the hyporesponsiveness in chronic HBV patients. Re-
cently, another regulatory T-cell type, besides CD4+CD25+
Treg, has been described. These so called T regulatory type
1 cells (Tr1) are CD4 positive cells, and their suppression is
mediated through an IL10 dependent mechanism (Foussat et
al., 2003). These Tr1 cells also play a dominant role in the
latent immune response against Epstein–Barr virus (Marshall
et al., 2003) and could be responsible for part of the IL10
production by PBMC observed in patients with a chronic
HBV infection (Hyodo et al., 2003). Since the viral load
reduction caused by adefovir is not sufficient to restore the
antiviral immune response, as depicted by the unchanged
production of the immunoregulatory cytokine IL10, combi-
nation therapy with antiviral drugs and immunomodulatory
therapy may be more successful in perpetuating the antiviral
immune response after treatment discontinuation.
In conclusion, viral load reduction induced by treatment with
adefovir results in a partial restoration of the impaired immune
response, as indicated by a decrease in percentages of Treg as
well as an increased HBV-specific proliferation and IFN-γ
production. IL10 production, however, remained unaffected.
The decrease in Treg is most likely established by the removal




Peripheral blood mononuclear cells (PBMC) from 12
chronic hepatitis B patients (10 males and 2 females, age 28
to 67 years; Table 1) were obtained at baseline and after 3 and 6
months of adefovir treatment (10 mg orally per day). At
baseline the median serum HBV DNA level was 1.7×108 geq/
ml (range 2.0×104 to 2.1×109), and median alanine trans-
aminase level (ALT), which is an indication of the extent of
hepatocellular injury, was 119 U/l (range 43–467). Six patients
were HBV e antigen (HBeAg) positive at baseline, and all
patients had biopsy proven chronic hepatitis with various degree
of liver inflammation and fibrosis. Seven patients were
treatment naive, and five patients had previously been treated
with IFN-α and lamivudine (n=3) or with entecavir (n=2).Patients co-infected with human immunodeficiency virus,
hepatitis A virus, hepatitis C virus (HCV) or hepatitis D virus
and patients with other types of hepatitis were excluded from
this study. Also patients who were pregnant or had received
antiviral, immune suppressive or immunomodulatory treatment
during the last 6 months were excluded from this study. All
participants gave informed consent before blood sampling.
Virological assessment
Serum HBeAg and anti-HBe were determined quantitatively
using the Abbott IMX system (Abbot Laboratories, North
Chicago, IL) according to the manufacturer's instructions.
Serum HBV DNAwas determined using an in-house developed
TaqMan Polymerase chain reaction based on the Eurohep
standard (detection limit, 373 geq/ml) (Applied Biosystems,
Foster City, CA) (Pas et al., 2000).
Isolation of the PBMC and flow cytometric analysis
PBMC were obtained by ficoll separation (Ficoll-Paque™
plus, Amersham Biosciences, Buckinghamshire, UK). They
were immediately frozen in RPMI 1640 (Bio Whittaker,
Verviers, Belgium) containing 20% fetal calf serum (Hyclone,
Logan, UT) and 10% dimethyl sulfoxide and stored at −135 °C.
PBMC from different time points were tested simultaneously to
avoid interassay variations in individual patients. Flow cyto-
metric analysis was performed on the stored samples using
fluorochrome conjugated antibodies specific for the surface
markers CD4, CD45RO and CD25 diluted in PBS/0.3% bovine
serum albumin. The cells were fixed by incubation with
intraprep reagent 1 and permeabilized by incubation with
intraprep reagent 2 (Beckman-Coulter, Marseille, France). Anti-
CTLA-4 antibody was added during permeabilization. The
following antibodies were used: anti-CD4-PerCP-Cy5.5 (SK3)
(Pharmingen, San Diego, CA), anti-CD45RO-APC (UCHL1)
(Becton Dickinson, San Jose, CA), anti-CD25-FITC (2A3)
(Becton Dickinson), anti-CTLA-4-PE (BNI3) (Immunotech,
Marseille, France). For the anti-CD45RO-APC, anti-CD25-
FITC and CTLA-4-PE, isotype matched control antibodies were
used to determine the level of background staining. The FoxP3
antibody staining was performed according to the manufac-
turer's instructions. Briefly, cells surface markers were stained
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PerCP-Cy5.5 (SK3) (Pharmingen). The cells were fixed and
permeabilized with Fix/perm buffer and permeabilization buffer
(eBiosciences, San Diego, Ca) anti-FoxP3-APC (PCH101)
(eBiosciences) was added during permeabilization. For anti-
CD25-PE and anti-FoxP3-APC isotype matched control anti-
bodies were used. After staining the cells were analyzed using a
four-color cytometer (FACScalibur™, CELLQuest Pro™ soft-
ware, Beckton Dickinson).
Proliferation assay
The proliferation of mainly CD4+ T cells was determined as
described earlier (Stoop et al., 2005). Briefly, PBMC were
cultured in triplicate in a concentration of 1×105 cells per well
in 100 μl RPMI 1640 (Bio Whittaker) containing 5% pooled
human serum (Department of Immunohematology and Blood-
bank, Leiden University Medical Center, Leiden, The Nether-
lands) and penicillin/streptomycin (Gibco, Paisley, UK). The
cells were stimulated with 1 μg/ml HBcAg (a kind gift by M.
van Roosmalen, Biomerieux, Boxtel, The Netherlands), 15
limits of flocculation/ml purified tetanus toxin (SVM, Biltho-
ven, The Netherlands) or not stimulated and cultured for 6 days.
After 5 days of incubation, the cells were pulsed with 0.25 μCi/
well of [3H]-thymidine (Radiochemical Centre, Amersham,
Little Chalfont, UK). The cells were harvested 16 h later.
Proliferation was determined by liquid scintillation counting of
the harvested cells.
IFN-γ and IL10 Elispot
The IFN-γ production of CD4+ T cells was determined by
Elispot as described earlier (Lau et al., 2002). Briefly, PBMC
were cultured in triplicate in a concentration of 1×105 cells per
well in 100 μl RPMI 1640 (Bio Whittaker) containing 5%
pooled human serum (Department of Immunohematology and
Bloodbank, Leiden University Medical Center) and penicillin/
streptomycin (Gibco). The cells were stimulated with either
1 μg/ml HBcAg, 20 μg/ml phytohemagglutinin (PHA) (Murex)
or 15 limits of flocculation/ml purified tetanus toxin (SVM) or
were left unstimulated and cultured for 24 h. After 24 h the
PBMC were transferred to antibody coated Elispot immuno-
plates. The IFN-γ Elispot kit was obtained from U-CyTech
(Utrecht, The Netherlands) and the IL10 Elispot kit was
obtained from Miltenyi Biotec (Bergisch Gladbach, Germany).
Both assays were performed according to the manufacturer's
instructions. The spots were counted using a Bioreader 3000
from BioSys (Karben, Germany). The number of spots depicted
represents the number of spots produced by stimulated cells
minus the number of spots produced by unstimulated cells.
In vitro effect of adefovir on the functioning of PBMC
9-(-2)-phosphonylmethoxy-ethyladenine (PMEA) is the
active metabolite of adefovir (Liu et al., 2004). PMEA was
kindly provided by Gilead Sciences Inc. (Foster City, CA).
PBMC from untreated HBV patients were stimulated withHBcAg in the presence of 100 ng/ml, 10 ng/ml, 1 ng/ml and
0.1 ng/ml of PMEA or no PMEA. Unstimulated PBMC and
unstimulated PBMC in the presence of 100 ng/ml of PMEA
were used as a negative control. The proliferation and IL10
production were determined by [3H]-thymidine incorporation
and Elispot for all conditions.
Statistical analysis
All flow cytometry and functional data were compared to
levels at baseline using a Wilcoxon matched pairs signed rank
sum test. SPSS version 11.5 for Windows (SPSS, Chicago, IL)
was used. Correlations were determined using Spearman's
correlation test. Results are given in mean±SEM, unless
specified otherwise.
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